

## PRODUCT INFORMATION

|   |   |
|---|---|
| <b>Clone ID</b>                         | DMC497  |
| <b>Target</b>                           | GPA33   |
| <b>Synonyms</b>                         | A33   |
| <b>Host Species</b>                     | Rabbit  |
| <b>Description</b>                      | PE-conjugated Anti-GPA33 antibody(DMC497); IgG1 Chimeric mAb  |
| <b>Delivery</b>                         | Under Development   |
| <b>Uniprot ID</b>                       | Q99795  |
| <b>IgG type</b>                         | Rabbit/Human Fc chimeric IgG1   |
| <b>Clonality</b>                        | Monoclonal  |
| <b>Reactivity</b>                       | Human   |
| <b>Applications</b>                     | Flow Cyt  |
| <b>Recommended Dilutions</b>            | Flow Cyt 1:100  |
| <b>Purification</b>                     | Purified from cell culture supernatant by affinity chromatography   |
| <b>Formulation &amp; Reconstitution</b> | Liquid□PBS with 0.05% Proclin300, 1% BSA  |
| <b>Storage &amp; Shipping</b>           | Store at 2°C-8°C for 6 months   |
| <b>Background</b>                       | The glycoprotein encoded by this gene is a cell surface antigen that is expressed in greater than 95% of human colon cancers. The open reading frame encodes a 319-amino acid polypeptide having a putative secretory signal sequence and 3 potential glycosylation sites. The predicted mature protein has a 213-amino acid extracellular region; a single transmembrane domain; and a 62-amino acid intracellular tail. The sequence of the extracellular region contains 2 domains characteristic of the CD2 subgroup of the immunoglobulin (Ig) superfamily. [provided by RefSeq; Jul 2008] |
| <b>Usage</b>                            | Research use only   |
| <b>Conjugate</b>                        | PE-conjugated   |
| <b>DIMA Disclaimer</b>                  | All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.  |

